Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

Covid19 Clinical Trial

Official title: A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19

Status Completed

Clinical Trial Summary

An open label clinical study to evaluate the safety and the efficacy of MesenCure, an allogeneic cell therapy product, for the treatment of the pulmonary manifestations in COVID19 patients

Clinical Trial Description

Primary endpoint: The IV administration of MesenCure is safe under the following conditions:

in subjects hospitalized with COVID19 moderate to severe disease, defined upon clinical situation and radiologic findings.

Secondary endpoint: The IV administration of MesenCure is efficacious under the following conditions:

Clinical parameters: Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, hospitalization duration.

______________________________________________________ Laboratory findings: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels.

______________________________________________________ Radiologic findings: pulmonary infiltrates, pleural effusion. ;

Related Conditions & MeSH terms

• COVID-19
• Covid19

• NCT number: NCT04716998
• Study type: Interventional
• Source: BonusBio Group Ltd
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 14, 2021
• Completion date: January 31, 2022